AU2002248381A1 - Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics - Google Patents

Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics

Info

Publication number
AU2002248381A1
AU2002248381A1 AU2002248381A AU2002248381A AU2002248381A1 AU 2002248381 A1 AU2002248381 A1 AU 2002248381A1 AU 2002248381 A AU2002248381 A AU 2002248381A AU 2002248381 A AU2002248381 A AU 2002248381A AU 2002248381 A1 AU2002248381 A1 AU 2002248381A1
Authority
AU
Australia
Prior art keywords
erk
dependence
inhibition
reduce
opioid analgesics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002248381A
Inventor
Howard B. Gutstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2002248381A1 publication Critical patent/AU2002248381A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002248381A 2001-01-25 2002-01-25 Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics Abandoned AU2002248381A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26433601P 2001-01-25 2001-01-25
US60/264,336 2001-01-25
PCT/US2002/002128 WO2002058687A2 (en) 2001-01-25 2002-01-25 Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics

Publications (1)

Publication Number Publication Date
AU2002248381A1 true AU2002248381A1 (en) 2002-08-06

Family

ID=23005591

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002248381A Abandoned AU2002248381A1 (en) 2001-01-25 2002-01-25 Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics

Country Status (4)

Country Link
EP (1) EP1377279A2 (en)
AU (1) AU2002248381A1 (en)
CA (1) CA2435038A1 (en)
WO (1) WO2002058687A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2017058007A1 (en) 2015-10-01 2017-04-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452877B2 (en) 2002-03-15 2008-11-18 Rytek Methods for treating digestive functional pathologies
FR2837103B1 (en) * 2002-03-15 2004-07-09 Rytek COMPOSITIONS FOR THE TREATMENT OF DIGESTIVE FUNCTIONAL CONDITIONS
FR2844201A1 (en) * 2002-09-06 2004-03-12 Rytek Use of compound that controls the opening of intestinal epithelium tight junctions for prevention and cure of hyperalgesic intestinal disorders
FR2879100B1 (en) 2004-12-09 2007-07-06 Lionel Bueno COMPOSITIONS FOR THE TREATMENT OF OCULAR SURFACE PATHOLOGIES AND RETINA
US8501740B2 (en) * 2007-10-09 2013-08-06 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain and addiction with inhibitors of certain growth factor receptors
WO2021016190A1 (en) * 2019-07-19 2021-01-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for modulating drug-use disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058699A1 (en) * 2000-06-30 2002-05-16 Sweatt J. David Methods for treating seizure disorders by inhibiting MAPK pathway activation

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2017058007A1 (en) 2015-10-01 2017-04-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition

Also Published As

Publication number Publication date
CA2435038A1 (en) 2002-08-01
EP1377279A2 (en) 2004-01-07
WO2002058687A3 (en) 2003-10-09
WO2002058687A2 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
AU2001286857A1 (en) Hybrid substrate with embedded capacitors and methods of manufacture
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
WO2002025415A8 (en) Systems and methods for preventing unauthorized use of digital content
AU2001250958A1 (en) Continuous processing of thin-film batteries and like devices
AU2001280849A1 (en) Electronic assembly comprising interposer with embedded capacitors and methods of manufacture
AU2001297724A1 (en) Electronic game enhancement systems and methods
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU6041599A (en) Time-based disablement of equipment
AU2001257127A1 (en) Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
AU2002331897A1 (en) Phytate polynucleotides and methods of use
AU2002357735A1 (en) Electronic door viewer and method of use
AU2003262145A1 (en) Access disconnection systems and methods
AU2001288452A1 (en) System and methods for the flexible usage of electronic content in heterogeneousdistributed environments
AU2002248381A1 (en) Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001282884A1 (en) Electronic component and method of manufacture
AU4825300A (en) Methods for inhibiting cutaneous inflammation and hyperpigmentation
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2001255090A1 (en) Cdk inhibitors having 3-hydroxychromen-4-one structure
AU2002356276A1 (en) Quinline derivates and their use as mek inhibitors
AU2001281771A1 (en) Brand positioning within electronic personal devices
AU2001259549A1 (en) Methods and systems for applications to interact with hardware
AU1202601A (en) All-organic corrosion inhibitor composition and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase